Klaus D
Z Kardiol. 1985;74 Suppl 7:153-69.
Left ventricular hypertrophy is the consequence of a structural adaptation of the heart in response to the chronic pressure load, leading to a reduction of the increased systolic wall stress. Studies in spontaneously hypertensive rats have shown, that left ventricular hypertrophy can be influenced by various, but not all antihypertensive agents. Alpha-methyldopa, captopril, beta-blockers and calcium channel blockers resulted in reversal of hypertrophy. Treatment with diuretics, hydralazine or minoxidil did not increase or alter degree of myocardial hypertrophy despite normalization of blood pressure. The biochemical profile after reversal of hypertrophy differs according to antihypertensive therapy, i.e. alpha-methyldopa induces an increase in collagen content, whereas captopril does not alter the collagen content of the myocardium. Adrenergic factors play an important role in modulating the response of the heart. In clinical studies the reduction in cardiac mass does not depend solely on the antihypertensive effect on blood pressure levels. There is only a weak correlation between decrease of left ventricular hypertrophy and fall of blood pressure level, as is shown in 12 patients with essential hypertension, treated with captopril over 6 months. The degree of regression of hypertrophy is influenced by stability of blood pressure control (diurnal variations and response to stress are more important than single casual values), neurohumoral response, presence of associated cardiac diseases, cause and severity of hypertension, genetic factors and age. We studied the regression of left ventricular hypertrophy by M-mode-echocardiography in 12 patients with mild or moderate essential hypertension during a 6-month therapy with captopril (50-75 mg p.d.) and hydrochlorothiazide (50 mg p.d.). In 11 of 12 patients captopril treatment resulted in a reduction of LV-mass of 30.9 +/- 15.1% and wall thickness. Peak systolic and endsystolic wall stress decreased significantly (-29.1% and -27.2%, resp.) after blood pressure reduction, but were still slightly elevated. Ejection fraction increased by 5.4% (p less than or equal to 0.05). 6 hypertensive patients treated for 6 months with metoprolol (150 mg p.d.) and hydrochlorothiazide (50 mg p.d.) do not show significant reduction of LV-mass (-6.5%). Peak and endsystolic wall stress were significantly reduced (-33.1% and -11.5%, resp.) as in captopril therapy. In 34 patients with severe hypertension treated with captopril, hydrochlorothiazide and metoprolol over 30 months, we observed a decline in the Sokolow-Lyon-Index from 4.8 +/- 1.1 mV to 3.8 +/- 0.5 mV after 6 months.(ABSTRACT TRUNCATED AT 400 WORDS)
左心室肥厚是心脏对慢性压力负荷产生结构适应性变化的结果,可使增加的收缩期壁应力降低。对自发性高血压大鼠的研究表明,左心室肥厚会受到多种(但并非所有)抗高血压药物的影响。α-甲基多巴、卡托普利、β受体阻滞剂和钙通道阻滞剂可使肥厚逆转。使用利尿剂、肼屈嗪或米诺地尔治疗,尽管血压恢复正常,但并未增加或改变心肌肥厚程度。肥厚逆转后的生化特征因抗高血压治疗方法而异,即α-甲基多巴可使胶原蛋白含量增加,而卡托普利不会改变心肌的胶原蛋白含量。肾上腺素能因子在调节心脏反应中起重要作用。临床研究表明,心脏重量的减轻并不完全取决于对血压水平的降压作用。左心室肥厚的减轻与血压水平的下降之间仅有微弱的相关性,如12例原发性高血压患者接受卡托普利治疗6个月所示。肥厚消退的程度受血压控制的稳定性(昼夜变化和对压力的反应比单次偶然值更重要)、神经体液反应、相关心脏疾病的存在、高血压的病因和严重程度、遗传因素以及年龄的影响。我们通过M型超声心动图研究了12例轻度或中度原发性高血压患者在接受卡托普利(每日50 - 75毫克)和氢氯噻嗪(每日50毫克)治疗6个月期间左心室肥厚的消退情况。12例患者中有11例接受卡托普利治疗后左心室质量减少了30.9±15.1%,室壁厚度也有所减少。血压降低后,收缩期峰值和舒张末期壁应力显著下降(分别下降29.1%和27.2%),但仍略有升高。射血分数增加了5.4%(P≤0.05)。6例高血压患者接受美托洛尔(每日150毫克)和氢氯噻嗪(每日50毫克)治疗6个月,左心室质量未显著降低(-6.5%)。收缩期峰值和舒张末期壁应力与卡托普利治疗一样显著降低(分别下降33.1%和11.5%)。在34例重度高血压患者接受卡托普利、氢氯噻嗪和美托洛尔治疗30个月后,我们观察到6个月后索科洛 - 里昂指数从4.8±1.1毫伏降至3.8±0.5毫伏。(摘要截选至400字)